On the other hand, 177Lu-PSMA-617 targets prostate-specific membrane antigen (PSMA), a cell-surface protein enriched in prostate cancer, which is used to treat metastatic prostate cancer (52). Here, FOLH1 is linked to prostate carcinoma.